TTD | Drug: D0A5MC

Drug General Information
Drug ID	D0A5MC
Former ID	DCL000169
Drug Name	MLN8054
Synonyms	ZZL; MLN-8054
Drug Type	Small molecular drug
Indication	Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]		Phase 1	[522281], [541037]
Therapeutic Class	Anticancer Agents
Company	Millenium; Takeda
Formula	C25H15ClF2N4O2
InChI	InChI=1S/C25H15ClF2N4O2/c26-15-6-9-17-18(10-15)23(21-19(27)2-1-3-20(21)28)29-11-14-12-30-25(32-22(14)17)31-16-7-4-13(5-8-16)24(33)34/h1-10,12H,11H2,(H,33,34)(H,30,31,32)
InChIKey	HHFBDROWDBDFBR-UHFFFAOYSA-N
CAS Number	CAS 869363-13-3
PubChem Compound ID	11712649
PubChem Substance ID	16817521, 23803070, 50100109, 75812624, 85240458, 87325745, 92728686, 103565670, 103904597, 117695998, 123055394, 124756998, 125163803, 131480681, 134338844, 134964414, 135686180, 135686181, 135686202, 135686203, 136340201, 136367298, 136920349, 137242800, 137739931, 152258105, 152344040, 160646944, 162011816, 162037433, 162723440, 163642777, 164193990, 164763083, 170496031, 174006403, 174531092, 177749042, 178102323, 180190865, 186022471, 198945325, 215776778, 223258872, 223579841, 223704701, 225331045, 226922686, 242059849, 244479327
Target and Pathway
Target(s)	Aurora kinase A	Target Info	Inhibitor	[536401], [536474], [551717]
KEGG Pathway	Oocyte meiosis
Pathway Interaction Database	Aurora B signaling
	Signaling by Aurora kinases
	Integrin-linked kinase signaling
	PLK1 signaling events
	Aurora A signaling
Reactome	APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Reactome	Regulation of PLK1 Activity at G2/M Transition
WikiPathways	EGF/EGFR Signaling Pathway
	JAK/STAT
	Gastric Cancer Network 1
	Integrated Breast Cancer Pathway
	APC/C-mediated degradation of cell cycle proteins
References
Ref 522281	ClinicalTrials.gov (NCT00652158) A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies. U.S. National Institutes of Health.
Ref 541037	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5696).
Ref 536401	MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007 Jun;27(12):4513-25. Epub 2007 Apr 16.
Ref 536474	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 551717	Clinical pipeline report, company report or official report of Takeda (2009).

Drug Information